These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26526856)

  • 1. Prevalence of pseudobulbar affect symptoms and clinical correlates in nursing home residents.
    Foley K; Konetzka RT; Bunin A; Yonan C
    Int J Geriatr Psychiatry; 2016 Jul; 31(7):694-701. PubMed ID: 26526856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical, behavioral, and treatment differences in nursing facility residents with dementia, with and without pseudobulbar affect symptomatology.
    Zarowitz BJ; O'Shea T
    Consult Pharm; 2013 Nov; 28(11):713-22. PubMed ID: 24217191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PRISM: a novel research tool to assess the prevalence of pseudobulbar affect symptoms across neurological conditions.
    Brooks BR; Crumpacker D; Fellus J; Kantor D; Kaye RE
    PLoS One; 2013; 8(8):e72232. PubMed ID: 23991068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of pseudobulbar affect symptoms in the nursing home setting: Development and assessment of a screening tool.
    Allen C; Zarowitz B; O'Shea T; Peterson E; Yonan C; Waterman F
    Geriatr Nurs; 2018; 39(1):54-59. PubMed ID: 28807457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudobulbar affect: an under-recognized and under-treated neurological disorder.
    Work SS; Colamonico JA; Bradley WG; Kaye RE
    Adv Ther; 2011 Jul; 28(7):586-601. PubMed ID: 21660634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inappropriate crying and laughing in Parkinson disease and movement disorders.
    Siddiqui MS; Fernandez HH; Garvan CW; Kirsch-Darrow L; Bowers D; Rodriguez RL; Jacobson CE; Rosado C; Vaidyanathan S; Foote KD; Okun MS
    World J Biol Psychiatry; 2009; 10(3):234-40. PubMed ID: 18609421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudobulbar affect: prevalence and quality of life impact in movement disorders.
    Strowd RE; Cartwright MS; Okun MS; Haq I; Siddiqui MS
    J Neurol; 2010 Aug; 257(8):1382-7. PubMed ID: 20376475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pseudobulbar Affect: An Overview.
    Goldin DS
    J Psychosoc Nurs Ment Health Serv; 2020 Sep; 58(9):19-24. PubMed ID: 32609863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laughter, crying and sadness in ALS.
    Thakore NJ; Pioro EP
    J Neurol Neurosurg Psychiatry; 2017 Oct; 88(10):825-831. PubMed ID: 28572273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of pseudobulbar affect symptoms in Veterans with possible traumatic brain injury.
    Fonda JR; Hunt PR; McGlinchey RE; Rudolph JL; Milberg WP; Reynolds MW; Yonan C
    J Rehabil Res Dev; 2015; 52(7):839-49. PubMed ID: 26744849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PSEUDOBULBAR AFFECT IN MULTIPLE SCLEROSIS PATIENTS.
    Vidović V; Rovazdi MČ; Kraml O; Kes VB
    Acta Clin Croat; 2015 Jun; 54(2):159-63. PubMed ID: 26415311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dextromethorphan/quinidine for the treatment of pseudobulbar affect.
    Patatanian E; Casselman J
    Consult Pharm; 2014 Apr; 29(4):264-9. PubMed ID: 24704895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudobulbar affect: burden of illness in the USA.
    Colamonico J; Formella A; Bradley W
    Adv Ther; 2012 Sep; 29(9):775-98. PubMed ID: 22941524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Compounded Dextromethorphan-Quinidine Suspension for Pseudobulbar Affect in Hospice Patients.
    Wahler RG; Reiman AT; Schrader JV
    J Palliat Med; 2017 Mar; 20(3):294-297. PubMed ID: 27997281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychotropic use and associated neuropsychiatric symptoms among patients with dementia in the USA.
    Maust DT; Langa KM; Blow FC; Kales HC
    Int J Geriatr Psychiatry; 2017 Feb; 32(2):164-174. PubMed ID: 26889640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pseudobulbar Affect Correlates With Mood Symptoms in Parkinsonian Disorders but Not Amyotrophic Lateral Sclerosis.
    Patel N; Combs H; York M; Phan C; Jimenez-Shahed J
    J Neuropsychiatry Clin Neurosci; 2018; 30(3):214-219. PubMed ID: 29505320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The psychopharmacology of pseudobulbar affect.
    Nguyen L; Matsumoto RR
    Handb Clin Neurol; 2019; 165():243-251. PubMed ID: 31727215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of Pseudobulbar Affect (PBA) in Parkinson's Disease: An Underrecognized Patient Burden.
    Falconer R; Whitney D; Walters H; Rogers S
    Cureus; 2021 Nov; 13(11):e19960. PubMed ID: 34868793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.
    Pattee GL; Wymer JP; Lomen-Hoerth C; Appel SH; Formella AE; Pope LE
    Curr Med Res Opin; 2014 Nov; 30(11):2255-65. PubMed ID: 25062507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dextromethorphan/quinidine: in pseudobulbar affect.
    Garnock-Jones KP
    CNS Drugs; 2011 May; 25(5):435-45. PubMed ID: 21476614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.